LOS ANGELES, CA -- (Marketwire) -- 01/18/13 -- A significant bunch of biotech deals were being…
Continue ReadingTag: lpath
Lpath Ranks Eighth Fastest Growing Biotechnology Company and 60th Overall Among N. America-s Fastest Growing Companies in Deloitte-s 2012 Technology Fast 500
Aggressive Growth Attributed to Leadership in Lipid-Targeted Therapeutics for the Treatment of a Wide Variety of…
Continue ReadingLpath Appoints Daniel L. Kisner, M.D. to Board of Directors
SAN DIEGO, CA -- (Marketwire) -- 08/01/12 -- Lpath, Inc. (OTCQB: LPTN), the industry leader in…
Continue ReadingNew Published Paper Shows Efficacy of Lpath-s Anti-LPA Antibody, Lpathomab, in Spinal Cord Injury Models
Key Publication Further Validates Lpath-s Approach to Targeting Bioactive Lipids as a Viable Platform for Drug…
Continue ReadingLpath Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab
Key Patent Further Validates Lpath-s ImmuneY2 Platform as a Viable Platform for Drug Discovery
Continue ReadingLpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source
Management to Host Investor Conference Call Tomorrow, Friday, January 27 at 8:45 a.m. ET
Continue ReadingLpath Schedules Investor Update Conference Call for Thursday, October 27, 2011 at 4:30 p.m. ET
SAN DIEGO, CA -- (Marketwire) -- 10/21/11 -- Lpath, Inc. (OTCBB: LPTN), the industry leader in…
Continue Reading